BidaskClub Lowers EXACT Sciences (NASDAQ:EXAS) to Hold

BidaskClub downgraded shares of EXACT Sciences (NASDAQ:EXAS) from a buy rating to a hold rating in a research note released on Wednesday, BidAskClub reports.

Several other equities analysts have also recently weighed in on the stock. Canaccord Genuity lifted their price objective on shares of TELUS from C$51.00 to C$52.00 in a research report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price objective on the stock in a research report on Monday, July 8th. Craig Hallum lifted their price objective on shares of 1-800-Flowers.Com from $26.00 to $20.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. Jefferies Financial Group lifted their price objective on shares of EXACT Sciences from $100.00 to $115.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. Finally, BTIG Research lifted their price objective on shares of Apple to $234.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of Buy and an average target price of $109.82.

NASDAQ EXAS opened at $114.88 on Wednesday. EXACT Sciences has a twelve month low of $47.78 and a twelve month high of $121.98. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. The stock has a market cap of $14.84 billion, a PE ratio of -84.47 and a beta of 1.64. The business’s 50 day moving average price is $113.12.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The firm had revenue of $162.00 million for the quarter, compared to analysts’ expectations of $153.07 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue for the quarter was up 79.4% on a year-over-year basis. On average, equities research analysts expect that EXACT Sciences will post -2.2 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Gilder Gagnon Howe & Co. LLC lifted its position in EXACT Sciences by 5.7% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 2,005,394 shares of the medical research company’s stock worth $173,707,000 after acquiring an additional 107,603 shares during the last quarter. Geode Capital Management LLC lifted its position in EXACT Sciences by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 1,197,840 shares of the medical research company’s stock worth $75,583,000 after acquiring an additional 69,128 shares during the last quarter. Eagle Asset Management Inc. lifted its position in EXACT Sciences by 10.0% during the 1st quarter. Eagle Asset Management Inc. now owns 1,096,623 shares of the medical research company’s stock worth $94,989,000 after acquiring an additional 100,072 shares during the last quarter. Norges Bank acquired a new position in EXACT Sciences during the 4th quarter worth $67,273,000. Finally, CIBC Private Wealth Group LLC lifted its position in EXACT Sciences by 15.5% during the 1st quarter. CIBC Private Wealth Group LLC now owns 1,049,462 shares of the medical research company’s stock worth $90,904,000 after acquiring an additional 140,825 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: Futures Contract

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.